On June 16, 2026 Silexion Therapeutics Corp. ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, reported that Company management, including the Company’s Chief Executive Officer, Ilan Hadar, and the Company’s Chief Financial Officer, Mirit Horenshtein-Hadar, will attend the 2026 BIO International Convention, taking place on June 22-25 in San Diego, CA.  

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Silexion’s management will host one-on-one meetings during the BIO Convention. Interested parties should contact Silexion company representative to arrange a meeting.

(Press release, Silexion Therapeutics, JUN 16, 2026, View Source [SID1234668767])